Baxter to acquire Claris Injectables for $625 million

Baxter International entered a definitive agreement to acquire Claris Injectables Limited, a subsidiary of Claris Lifesciences, for approximately $625 million. The deal is expected to close in the second half of 2017.

“Sterile medication production is a core competency for Baxter, which manufactures a broad range of essential generic injectable medications.”baxter.ca

• 2 sources
• baxter.caBaxter to Expand Portfolio of Essential Generic Injectable Medicines with Acquisition of Claris Injectables Limited | BaxterDec 15, 2016
• timesofindia.indiatimes.comBaxter buys Claris arm for Rs 4.2k cr - Times of IndiaTNNDec 15, 2016

Summarized from public sources; check the original articles before acting on it.